BSEParmax Pharma LtdHighNeutral
Announced Tue, 9 Jun · 08:51 IST

Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulation 3(1) And Regulation 4 Read with Regulation 13, Regulation 14 And Regulation ....

Open Offer TriggeredListed Co AcquisitionStrategic Transactions View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.0%1-day move
₹48.90
prior close
₹50.76
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+1.0+1.0+1.0+10.0+15.5+21.3+27.4+33.7+39.1+62.9+83.4
Up moveDown movePending
AI summary

Parmax Pharma Ltd, listed on BSE (Scrip Code: 540359), has received a Public Announcement for a mandatory open offer from Dhiren Chandulal Shah and Sunil Chinubhai Shah along with 10 persons acting in concert (PACs). The offer is to acquire up to 23,46,250 equity shares (26% of the expanded voting capital) from public shareholders at ₹42.80 per share, totaling about ₹10.04 crores. The offer was triggered by a Share Purchase Agreement to buy 12.77% stake from the existing promoter Gopani family at ₹35/share, combined with a preferential issue of shares and warrants at ₹36.50/share to the new acquirers. Post-transaction, the existing promoters will completely exit, and the new acquirers will take over control of the company, holding about 57% combined. The acquirers have stated no intention to delist the company.

Likely market impact

This is a change-of-control event for retail shareholders. Existing promoter family is exiting entirely, and a new group is taking over with a controlling stake. Public shareholders can tender shares at ₹42.80 (a premium over the SPA price of ₹35), and the open offer is not conditional on minimum acceptance, giving shareholders a clear exit option. The stock may see volatility around the offer window.